Aegerion appoints Marc Beer as CEO
This article was originally published in Scrip
Executive Summary
Aegerion Pharmaceuticals, a US-based biopharmaceutical company focused on the development and commercialisation of therapeutics to treat severe lipid disorders, has appointed Marc Beer as both CEO and a member of the board of directors. He has more than 20 years experience in biotechnology, pharmaceuticals and diagnostics. In 2000, he became the founding CEO of ViaCell, a biotech company specialising in the collection and preservation of umbilical cord blood stem cells. Mr Beer has also worked for Genzyme and Abbott Laboratories.